Nyrada (ASX:NYR) has commenced recruitment for its phase one clinical trial of its lead drug candidate NYR-BI03.

OncoSil Medical (ASX:OSL) has announced the appointment of Shelley Steyn as chief financial officer, effective 5 May.

Australian biotechnology company Noxopharm (ASX:NOX) has engaged Doherty Clinical Trials to conduct its upcoming phase 1 HERACLES trial.

Telix Pharmaceuticals (ASX:TLX) has completed the transaction to expand its theranostic pipeline with new candidates targeting Fibroblast Activation Protein (FAP), one of the most promising pan-cancer targets in nuclear medicine.

Proteomics International Laboratories (ASX:PIQ) has officially launched its first-in-class predictive test for diabetic kidney disease, PromarkerD, in Australia.

Argent BioPharma (ASX:RGT) has signed an agreement with Dr Shlomo Sadoun granting him exclusive rights to facilitate a commercial transaction for the company's Malta-based GMP-certified manufacturing facility.

Australian company Anatara Lifesciences (ASX:ANR) has updated investors on the GaRP-Irritable Bowel Syndrome phase 2 trial and the anti-obesity project.

PolyNovo (ASX:PNV) has announced that its chief executive officer, Swami Raote, will officially leave the company in June but will step down immediately.

Respiratory imaging technology company 4DMedical (ASX:4DX) has announced the renewal and extension of the contract for its pulmonary function software-as-a-service analysis with the Cleveland Clinic.

Clinical-stage oncology company Prescient Therapeutics (ASX:PTX) has announced that Dr James Campbell will succeed Steven Engle as its chair.

A new report by Telix says the tens of thousands of Australians could miss out on a new era of cancer treatment without action from the government to secure the viability of the nuclear medicine sector, including enforcing regulatory standards.

Medtech entrepreneurs are invited to showcase their innovations at the 2025 Early-Stage Innovation Forum (ESIF), a premier platform for emerging developers to present their cutting-edge solutions at the AusMedtech 2025 conference in Sydney 6 – 8 May.

Clinical-stage biotechnology company Vaxxas has announced the publication of data supporting the potential use of its high-density microarray patch technology to deliver nucleic acid-based vaccines in collaboration with The University of Queensland and Technovalia.

Australian company Atmo Biosciences has announced the publication of pivotal clinical study data in Clinical Gastroenterology and Hepatology.

"Through his leadership, BioMelbourne Network has solidified its position within the Victorian health technologies sector, delivering positive outcomes for members and stakeholders and contributing to the advancement of life sciences," said the organisation.

The George Institute for Global Health, a leading medical research organisation, has appointed Dr Paul Schreier as its new board chair.

Australian startup company Cortical Labs has launched CL1, the world’s first commercial biological computer, which fuses lab-cultivated neurons from human stem cells with silicon to create a new, more advanced form of artificial intelligence.